Brief: Ryvu Therapeutics Extends Research Collaboration And Exclusive License Agreement With BioNTech Until Nov 29, 2028
16/03/2026 16:32
March 16 (Reuters) - Ryvu Therapeutics SA RVU.WA: EXTENDS RESEARCH COLLABORATION AND EXCLUSIVE LICENSE AGREEMENT WITH BIONTECH SE AGREEMENT EXTENDED FOR AN ADDITIONAL YEAR, UNTIL NOVEMBER 29, 2028 Source text: ID:nEM2z8snsa Further company coverage: RVU.WA (Reporting by Gdansk Newsroom) ((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))
Recent news on Ryvu Therapeutics SA
See all newsBrief: Ryvu Therapeutics Q1 Net Loss 12.6 Million Zlotys
Brief: Ryvu Therapeutics Updates Romacyclib Development Strategy
Brief: Ryvu Therapeutics FY Net Loss At 101.2 Mln Zlotys
Brief: Ryvu Therapeutics Extends Research Collaboration And Exclusive License Agreement With BioNTech Until Nov 29, 2028
Brief: Ryvu Therapeutics Signs Grant Agreement With Poland's NCBR For PERO Project